Additionally, inhibition of ACSLs may increase tumor cell sensitivity to venetoclax, a BCL2 inhibitor [61], since electron transport chain Complex I and II activity is positively correlated with resistance to venetoclax, and we observed that TriC decreased expression of subunits of Complexes I and IV. Here, BCL2 is linked to neoplasm.